RxDoctor Payments Data

Diana Sandler, MD

Rheumatology · Hinsdale, ILNPI 1407088164

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,025 of the $19,228 with a category attached, or 67.7%. AbbVie accounts for 86.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $9,477 and has fallen 93.5% since, to $614 in 2025.

$19,228in general payments, 2019–2025

Across 62 payments — averaging $310.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Amgen$943
  • Novartis$458
  • Kyowa Kirin, Inc.$442
  • UCB, Inc.$237
  • AstraZeneca$176
  • plus $366 from 3 others

What the payments were for

  • Consulting fees$1,6008%
  • Speaking & faculty fees$13,02568%
  • Travel & lodging$4542%
  • Food & beverage$4,09421%
  • Education$550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie32$16,606
Amgen13$943
Novartis5$458
Kyowa Kirin, Inc.5$442
UCB, Inc.2$237
AstraZeneca2$176
Johnson & Johnson1$141
Radius Health, Inc.1$133
GSK1$92

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,228 in reported general payments places this provider in the 85th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$123,153
Medicare patients
450
Services billed
1,574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab34$259,609
Enbrel SureclickEtanercept29$211,693
XeljanzTofacitinib Citrate27$187,554
ForteoTeriparatide20$86,319
TymlosAbaloparatide28$73,158
Xeljanz XrTofacitinib Citrate12$69,759
KineretAnakinra11$60,243
BenlystaBelimumab11$55,686
Teriparatide15$50,216
Actemra ActpenTocilizumab12$28,985
ProliaDenosumab12$20,779
RasuvoMethotrexate/Pf26$14,461
Hydroxychloroquine Sulfate158$6,120
Risedronate Sodium44$3,874
Alendronate Sodium208$3,100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Radius Health, Inc.Tymlos$133$73,15828 claims
GSKBenlysta$92$55,68611 claims
AmgenProlia$943$20,77912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Hinsdale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →